Mоlimо vаs kоristitе оvај idеntifikаtоr zа citirаnjе ili оvај link dо оvе stаvkе:
https://open.uns.ac.rs/handle/123456789/15910
Nаziv: | Formulation buoyancy of nanoencapsulated gliclazide using primary, conjugated and deconjugated bile acids | Аutоri: | Mathavan S. Ionescu C. Božica Kovačević Momir Mikov Svetlana Goločorbin-Kon Mooranian A. Dass C. Al-Salami H. |
Ključnе rеči: | buoyancy;cell viability;drug tissue permeation;excipient stabilizing;gliclazide;muscle cells | Dаtum izdаvаnjа: | 1-јан-2019 | Čаsоpis: | Therapeutic Delivery | Sažetak: | © 2019 Newlands Press. Aim: Recent studies suggest potential applications of endogenously produced human bile acids as formulation-excipient and drug tissue permeation enhancers in Type 1 diabetes. We aimed to examine the stability, tissue permeation and ex vivo muscle-cell effects of microencapsulated gliclazide (G) incorporated with a primary (chenodeoxycholic acid [CDCA]), a secondary (ursodeoxycholic acid [UDCA]) or a tertiary (taurocholic acid [TCA]) bile acid. Materials & methods: Four formulations made of sodium alginate, CDCA, UDCA and TCA were examined for buoyancy, tissue-enhancing effects (in vivo) and local (ex vivo) viability effects. Results & conclusion: CDCA, UDCA and TCA improved buoyancy and cell viability but not tissue-specific uptake. G-TCA-sodium alginate microcapsules exerted hypoglycemic effects, suggesting significant improvement of G gut-uptake by TCA, possibly via improving buoyancy. | URI: | https://open.uns.ac.rs/handle/123456789/15910 | ISSN: | 20415990 | DOI: | 10.4155/tde-2019-0058 |
Nаlаzi sе u kоlеkciјаmа: | MDF Publikacije/Publications |
Prikаzаti cеlоkupаn zаpis stаvki
SCOPUSTM
Nаvоđеnjа
12
prоvеrеnо 10.05.2024.
Prеglеd/i stаnicа
20
Prоtеklа nеdеljа
7
7
Prоtеkli mеsеc
0
0
prоvеrеnо 10.05.2024.
Google ScholarTM
Prоvеritе
Аlt mеtrikа
Stаvkе nа DSpace-u su zаštićеnе аutоrskim prаvimа, sа svim prаvimа zаdržаnim, оsim аkо nije drugačije naznačeno.